期刊文献+

不同化疗方案对晚期卵巢癌治疗效果的对比 被引量:21

Comparison of Different Chemotherapy for Advanced Ovarian Cancer
下载PDF
导出
摘要 目的对比TC与TP方案应用于初次接受手术后化疗的晚期卵巢癌患者中的临床疗效及不良反应的差异。方法回顾性选取2011年1月-2014年12月晚期卵巢癌患者165例,TC方案组85例,TP方案组80例,收集其完整病例资料,对2组患者的治疗效果与不良反应情况进行对比分析。结果 TC方案组的临床有效率明显高于TP组,差异具有统计学意义(P<0.05)。TC方案组的治疗总的生活质量改善程度明显高于TP组,差异具有统计学意义(P<0.05);与TP组比较,TC组治疗期间的血小板下降明显高于TP组,但均不严重;恶心呕吐及肝肾功能毒性明显低于TP组,差异有统计学意义(P<0.05)。结论 TC方案治疗晚期卵巢癌可取得较好的临床疗效,不良反应相对较少,耐受程度高,对延长生存时间,改善患者生活质量具有重要意义。 Objective To compare the clinical efficacy and adverse reactions of TC and TP for advanced ovarian cancer. Methods Retrospective analysis of 165 cases of patients with advanced ovarian cancer were conducted. TC group had 85 cases, and TP group had 80 cases. The complete medical information of all patients were collected, and clinical efficacy and adverse reactions of the 2 groups were analyzed. Results The clinical effectiveness of TC group was obviously higher than TP group, and the difference was statistical significant ( P 〈 0.05 ). The overall quality of life of TC group was superior to TP group ( P 〈 0.05 ) ; Compared with TP group, the rate of platelet decline during treatment in TC group was obviously higher than TP group, but the condition were not serious. The rate of nausea and vomiting,liver and kidney toxicity in TC group were lower than TP group, and the differences were statistically significant ( P 〈 0.05). Conclusion Chemotherapy with TC for advanced ovarian cancer is effective with relatively small side effects and high degree of tolerance. It is of great significance to prolong the survival time and improve quality of life of patients.
出处 《实用癌症杂志》 2016年第3期437-439,共3页 The Practical Journal of Cancer
关键词 化疗 顺铂 紫杉醇 卡铂 卵巢癌 疗效 Chemotherapy Cisplatin Taxol Carboplatin Ovarian cancer Curative effect
  • 相关文献

参考文献5

  • 1Makasian GD, Decker DG, Webb MJ. Histology of epithelial tumors of theory: clinical usefulness and prognostic signifi- cance of the histologic classification and grading[J].Semin Oncol, 1975,2 ( 3 ) : 191-201.
  • 2李高辉,范秋虹.多西他赛联合卡铂治疗复发性卵巢癌的疗效观察[J].现代生物医学进展,2010,10(3):549-551. 被引量:9
  • 3曹泽毅.中华妇产科学[M].北京:人民卫生出版社,1999.2129.
  • 4Berry G, Billingham M, Alderman E, et al. Reduced cardio- toxicity of DOXIL in AIDS Kaposi's sarcoma patients com- pared to a matched control group of cancer patients given doxorubicin[J]. Proc Am Soc Clin Oncol, 1996,15 : 303- 308.
  • 5Moore KN,Herzog TJ,Lewin S,et al. A comparison of cis- platin/paclitaxel and carboplatin paclitaxel in stage 1VB, re- current or persistent eervieal cancer [J].Gynecol Oncol, 2007,105 (2) : 299-303.

二级参考文献10

  • 1路虹,王建东,孔为民.多西他赛作为一线用药治疗卵巢癌研究进展[J].肿瘤防治杂志,2005,12(15):1194-1196. 被引量:21
  • 2Latorro A,De Lena M,Catino A,et al.Epithelia ovirian cancer:second and third line chemotherapy.Int J Oncol,2002,21 (1): 179-181.
  • 3Pfisterer J, Ledermnn JA. Mangement of platinum - Sensitive Recurrent Ovarian Cancer [J]. Seminars in Oncology ,2006,33(suppl 6) : 22-26.
  • 4Harries M,Gore M. Part Ⅱ :chemotherapy for epithelial ovarian cancer-treatment of recurrent disease[J].Lancet Oncol,2002;3(9):537- 545.
  • 5Rose PG,Blessing J A,Ball H G,et al. A phase Ⅱ study of docetaxel in paclitaxel resistant ovarian and peritoneal carcinoma:a Gynecologic Oneology Group study.Gynecol Oncol,2003,88(2): 130-135.
  • 6Fulton B,Spencer C M.Docetaxel:A review of its pharmacodynamic and pharmacokinetic properties and therapeutic eficaey in the management of metastatic breast cancer.Drugs, 1996,51 (6): 1075-1079.
  • 7Vasey P A, Jayson G C, Gordon A, et al. Phase Ⅲ randomized trial of doetaxel - csrboplatin vemus paclitaxel - carboplatinas first - line chemotherapy for ovarian carcinoma. J Natl Cancer Inst,2004,96 (22): 1682-1685.
  • 8李洪君,刘丽影.复发性卵巢癌的诊治现状[J].临床肿瘤学杂志,2007,12(7):553-556. 被引量:16
  • 9逯华,陈日新.多西他赛联合卡铂治疗晚期复发性卵巢癌36例的疗效观察[J].广西医学,2008,30(7):1059-1060. 被引量:12
  • 10顾军,韩香,张磊.多西他赛用于卵巢癌治疗临床研究进展[J].天津药学,2008,20(5):68-70. 被引量:7

共引文献3241

同被引文献161

引证文献21

二级引证文献111

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部